Synthesis and cytotoxicity of novel indirubin-5-carboxamides.

Bioorg Med Chem

Department of Chemistry, Division of Food Chemistry and Toxicology, University of Kaiserslautern, Kaiserslautern, Germany.

Published: June 2010

Indirubins have been reported to act as potent inhibitors of protein kinases relevant to tumorigenesis and of tumor cell growth, but their development to antitumor drugs suffer from their poor water solubility. We synthesized a novel class of indirubin derivatives, indirubin-5-carboxamides, carrying amide substituents with basic centers. Quaternization or protonation of these alkylamino substituents provided indirubins with significantly improved solubility without loss of bioactivity.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmc.2010.04.066DOI Listing

Publication Analysis

Top Keywords

synthesis cytotoxicity
4
cytotoxicity novel
4
novel indirubin-5-carboxamides
4
indirubin-5-carboxamides indirubins
4
indirubins reported
4
reported potent
4
potent inhibitors
4
inhibitors protein
4
protein kinases
4
kinases relevant
4

Similar Publications

Breast cancer ranks as the second leading reason of cancer mortality among females globally, emphasizing the critical need for novel anticancer treatments. In current work, berberine-zinc oxide conjugated chitosan nanoparticles were synthesized and characterized using various characterization techniques. The cytotoxic effects of CS-ZnO-Ber NPs on MCF-7 cells were assessed using the MTT assay.

View Article and Find Full Text PDF

Human cancer cells xenografts to assess the efficacy of granulysin-based therapeutics.

Methods Cell Biol

January 2025

Apoptosis, Immunity and Cancer Group, Aragón Health Research Institute (IIS-Aragón), University of Zaragoza, Zaragoza, Spain. Electronic address:

9-kDa Granulysin is a protein present in the granules of human activated cytotoxic T lymphocytes and natural killer cells. It has been shown to exert cytolytic activity against a wide variety of microbes: bacteria, fungi, yeast and protozoa. Recombinant isolated granulysin is also capable of inducing tumor cell death, so it could be used as an anti-tumor therapy.

View Article and Find Full Text PDF

Evidence has shown that T-cell receptors (TCRs) that recognize the same epitopes may not be the exact TCR clonotypes but have slightly different TCR sequences. However, the changes in the genomic and transcriptomic signatures of these highly homologous T cells during immunotherapy remain unknown. Here, we examined the evolutionary features in circulating TCR clonotypes observed in tumors (tumor-infiltrating lymphocyte (TIL)-TCRs) by combining single-cell RNA/TCR sequencing of longitudinal blood samples and TCR sequencing of tumor tissue from a patient treated with anti-cytotoxic T-lymphocyte-associated protein 4/programmed cell death protein-1 therapy.

View Article and Find Full Text PDF

Background: B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 across various solid tumors and developed novel monoclonal antibodies (mAbs) targeting B7-H3 for CAR T cell therapy.

Methods: Expression of B7-H3 across various solid tumors was evaluated using RNA-seq data from TCGA, TARGET, and GTEx datasets and by flow cytometry staining.

View Article and Find Full Text PDF

This study successfully synthesised and characterised composites combining chitosan (CH), carboxymethyl cellulose (CMC), and various flavonoids (Fla). This innovative approach demonstrates the potential for developing functional materials with antioxidant and food preservation properties. The composites CH-Fla-CMC (1-5) was characterised using advanced techniques such as FT-IR, UV-Vis, XRD, SEM, TEM, and TGA, providing robust data on their structural, morphological, and thermal properties.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!